Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NCT05451849 is registered in ClinicalTrials.gov with TCR2 Therapeutics as lead sponsor.

NCT NCT05451849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05451849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Lead sponsor
TCR2 Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
June 21, 2022
Completion date
August 30, 2025
Enrollment
14 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal cancer, colorectal neoplasms, mesothelioma, mesothelioma peritoneum, mesothelioma, malignant, mesotheliomas pleural, non small cell lung cancer, ovarian adenocarcinoma, ovarian cancer, ovarian neoplasms, ovarian serous adenocarcinoma, pancreatic adenocarcinoma, pancreatic cancer, pancreatic neoplasms, tnbc - triple-negative breast cancer, triple negative breast cancer